Document is current
Any future updates will be listed below
-
Authors
Aldape, Kenneth
Brindle, Kevin M.
Chesler, Louis
Chopra, Rajesh
Gajjar, Amar
Gilbert, Mark R.
Gottardo, Nicholas
Gutmann, David H.
Hargrave, Darren
Holland, Eric C.
Jones, David T. W.
Joyce, Johanna A.
Kearns, Pamela
Kieran, Mark W.
Mellinghoff, Ingo K.
Merchant, Melinda
Pfister, Stefan M.
Pollard, Steven M.
Ramaswamy, Vijay https://orcid.org/0000-0002-6557-895X
Rich, Jeremy N.
Robinson, Giles W. https://orcid.org/0000-0001-7441-9486
Rowitch, David H.
Sampson, John H.
Taylor, Michael D.
Workman, Paul
Gilbertson, Richard J. https://orcid.org/0000-0001-7539-9472
- License Information
-
More Information
Article History
First Online: 7 February 2019
Competing interests
: P.W. and R.C. are employees of The Institute of Cancer Research (ICR), which has a commercial interest in a range of drug targets. The ICR operates a Rewards to Inventors scheme whereby employees of the ICR may receive financial benefit following commercial licensing of a project. P.W. is a consultant/scientific advisory board member for NextechInvest, Storm Therapeutics, Astex Pharmaceuticals and CV6 and holds stock in Chroma Therapeutics, NextInvest and Storm Therapeutics; he is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Director of the non-profit Chemical Probes Portal. R.C. is an advisor to Syncona Limited and holds equity in Celgene Corporation, e-Therapeutics and Monte Rosa Therapeutics. The other authors declare no competing interests.
